CelLBxHealth plc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ANPCY research report →
About the company
Headquartered in Guildford, United Kingdom, and established in 1994, CelLBxHealth plc (formerly known as ANGLE plc until October 2025) is a medical diagnostics company dedicated to advancing cancer detection. The firm's reach extends globally, with operations in the UK, Europe, and North America. CelLBxHealth's product portfolio features innovative medical devices such as the Parsortix PC1 system, specifically engineered to isolate and collect intact circulating tumor cells (CTCs) from the blood of metastatic breast cancer patients for subsequent user-validated analysis.
- CEO
- Peter Collins
- IPO
- 2015
- Employees
- 119
- HQ
- Guildford, GB
Price Chart
- Revenue
- $2.86M · 30.92%
- Net Income
- $-14,225,000 · 29.34%
- EPS
- $-0.48 · 37.65%
- Op Income
- $-15,096,000
- FCF YoY
- 8.11%
- 52W High
- $2.39
- 52W Low
- $0.07
- 50D MA
- $0.18
- 200D MA
- $0.63
- Beta
- 0.14
- Avg Volume
- 19.15K
Get TickerSpark's AI analysis on ANPCY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our ANPCY coverage
Recent articles, reports, and earnings notes.
No research on ANPCY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ANPCY report →Similar companies
Peers in the same neighborhood.